--- title: "Benitec Biopharma (BNTC) stock: news and investor profile" url: "https://aibio.space/companies/benitec-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Benitec Biopharma Inc. (NASDAQ: BNTC), United States. The directory classifies it as Biotechnology." --- BNTC Benitec Biopharma Inc. NASDAQ · United States # Benitec Biopharma (BNTC) news Distress · 2025-09-12 ## [Benitec Biopharma says two quarterly financial reports should not be relied on, plans restatement](https://aibio.space/news/benitec-biopharma-says-two-quarterly-financial-reports-should-not/) Benitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time. ## Latest Benitec Biopharma news 1. 2025-03-26 Financings [Benitec Biopharma prices $30 million stock sale at $13.00 per share](https://aibio.space/news/benitec-biopharma-prices-30-million-stock-sale-13-00-share/) Benitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself. ## Benitec Biopharma at a glance - **Ticker**: BNTC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $180.0 million ### Related companies - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Odyssey Therapeutics](https://aibio.space/companies/odyssey-therapeutics/) NASDAQ: ODTX - [LianBio](https://aibio.space/companies/lianbio/) OTC: LIANY - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [Provectus Biopharmaceuticals](https://aibio.space/companies/provectus-biopharmaceuticals/) OTC: PVCT - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA ### Also on NASDAQ - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) ALZN - [PRF Technologies](https://aibio.space/companies/prf-technologies/) PRFX - [Invivyd](https://aibio.space/companies/invivyd/) IVVD - [Veru](https://aibio.space/companies/veru/) VERU - [CorMedix](https://aibio.space/companies/cormedix/) CRMD - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) AMRX ## What Benitec Biopharma does Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on novel genetic medicines. Its lead product candidate, BB-301, is an AAV-based gene therapy for oculopharyngeal muscular dystrophy, or OPMD, a chronic, life-threatening genetic disorder. BB-301 is designed to permanently silence the disease-causing gene and simultaneously replace the mutant gene with a functional gene, an approach the company calls silence and replace. The underlying platform, DNA-directed RNA interference, or ddRNAi, combines RNA interference with viral delivery agents typically associated with gene therapy. BB-301 has Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union. The Investigational New Drug application for BB-301 was approved to proceed by the U.S. Food and Drug Administration in June 2023, and the first study subject was treated in the BB-301 Phase 1b/2a clinical trial in November 2023. The company says it will require additional financing to progress its product candidates through future inflection points. | Product or program | What it is | Stage | |---|---|---| | BB-301 | AAV-based silence and replace gene therapy for OPMD-derived dysphagia | Phase 1b/2a clinical trial | | ddRNAi platform | DNA-directed RNA interference combined with AAV viral vectors | | Summarised from the company's [10-K filed Sep 14, 2026](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/bntc-20260630.htm). ## Benitec Biopharma annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$23.4 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | [$18.3 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | | Net income (loss) | [-$45.5 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | [-$37.9 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | | Cash from operations | [-$16.5 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | [-$23.6 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | | Cash and equivalents | [$180.0 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | [$97.7 million](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $180.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Benitec Biopharma What is the ticker symbol of Benitec Biopharma? Benitec Biopharma Inc. trades under the ticker BNTC on NASDAQ. Where is Benitec Biopharma listed? Benitec Biopharma Inc. is listed on NASDAQ. What is the SEC CIK of Benitec Biopharma? The SEC Central Index Key (CIK) for Benitec Biopharma Inc. is 1808898. Its filings are on SEC EDGAR. How many shares does Benitec Biopharma have outstanding? 34,882,726 shares as of 2026-09-04, per the cover page of its 10-K filed 2026-09-14. Which country or territory is Benitec Biopharma listed under? Our directory records Benitec Biopharma Inc. under United States. What does Benitec Biopharma do? Our directory classifies Benitec Biopharma Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Benitec Biopharma? The ISIN recorded for Benitec Biopharma Inc. is US08205P2092. Does aibio.space cover Benitec Biopharma? aibio.space lists Benitec Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Benitec Biopharma incorporated? SEC records list its state or country of incorporation as DE. What does Benitec Biopharma develop? Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on novel genetic medicines. Its lead product candidate, BB-301, is an AAV-based gene therapy for oculopharyngeal muscular dystrophy, or OPMD, a chronic, life-threatening genetic disorder. What is BB-301 from Benitec Biopharma? BB-301: AAV-based silence and replace gene therapy for OPMD-derived dysphagia Stage: Phase 1b/2a clinical trial. What is ddRNAi platform from Benitec Biopharma? ddRNAi platform: DNA-directed RNA interference combined with AAV viral vectors Is Benitec Biopharma profitable? Benitec Biopharma Inc. reported a net loss of $45.5 million for the fiscal year ended Jun 30, 2026, and used $16.5 million of cash in operations, per its annual report to the SEC. How much does Benitec Biopharma spend on research and development? $23.4 million in the fiscal year ended Jun 30, 2026, per its annual report. How much cash does Benitec Biopharma have? $180.0 million in cash at Jun 30, 2026, per its 10-K. ## Investor discussion: Benitec Biopharma Members talk about Benitec Biopharma (BNTC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Benitec Biopharma, newest first. Each line links the filing it comes from. 1. 2026-09-30 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/bntc-20260929.htm) 2. 2026-09-24 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/bntc-20260918.htm) 3. 2026-09-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/bntc-20260630.htm) 4. 2025-11-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312525267262/d80934d424b5.htm) 5. 2025-09-22 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312525211361/d57150d10k.htm) 6. 2025-09-22 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312525211549/d95525ds3.htm) 7. 2025-09-12 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1808898/000095017025114530/bntc-20250910.htm) 8. 2025-03-26 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312525063235/d931233dex991.htm) 9. 2024-11-01 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1808898/000119312524249919/d888703ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BNTC on TradingView](https://www.tradingview.com/symbols/NASDAQ-BNTC/). ## SEC filings and registration - **SEC name**: Benitec Biopharma Inc. - **CIK**: 1808898 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BNTC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3940 TRUST WAY, HAYWARD, CA, 94545 - **Phone**: (510) 780-0819 - **Shares outstanding**: 34,882,726 as of 2026-09-04 (10-K filed 2026-09-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1808898/000119312526426733/bntc-20261020.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526413177/bntc-20261005.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/bntc-20260929.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/bntc-20260918.htm) filed 2026-09-24 - [S-3](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390758/d123814ds3.htm) filed 2026-09-14 - [10-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390570/bntc-20260630.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-20260914.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/bntc-20260522.htm) filed 2026-05-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808898), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Benitec Biopharma Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BNTC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Benitec Biopharma Inc. - **Ticker**: BNTC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US08205P2092 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BNTC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/benitec-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Benitec Biopharma (BNTC) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/benitec-biopharma/